Dual Diagnosis Management — MCQs
Which of the following is a validated screening tool for alcohol use disorder?
What is considered the most effective treatment for Borderline Personality Disorder?
Atomoxetine is used in the management of which of the following conditions?
In which of the following conditions is behavior therapy considered most effective?
Which of the following treatments cannot be used for management of Obsessive Compulsive Disorder (OCD)?
A patient stopped alcohol consumption for 3 days and presented with irritability, disorientation, paranoid delusions, agitation, visual hallucinations, and altered sensorium. What is the likely diagnosis in this case?
Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
Which of the following statements accurately describes dual sex therapy?
Provision of the Mental Health Act 2017, based on WHO guidelines, includes all, except:
Choose the correctly matched pairs regarding the drugs used in schizophrenia: 1. D2 antagonism: Reduces positive symptoms 2. 5HT2A antagonism: Reduces negative symptoms 3. 5HT1A agonism: Weight loss 4. Muscarinic antagonism: Reduces extrapyramidal symptoms
Dual Diagnosis Management Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is a validated screening tool for alcohol use disorder?
- A. AUDIT
- B. CAGE questionnaire
- C. SADQ
- D. All of the options (Correct Answer)
Explanation: ***CAGE questionnaire and AUDIT*** - Both **CAGE** and **AUDIT** are widely validated screening tools specifically designed for alcohol use disorder [1]. - **CAGE** is a brief 4-item tool focusing on **C**ut down, **A**nnoyed, **G**uilty, and **E**ye-opener - ideal for quick screening in clinical settings [1]. - **AUDIT** (Alcohol Use Disorders Identification Test) is a comprehensive 10-item tool assessing consumption patterns, drinking behaviors, and alcohol-related problems. - AUDIT is considered the **gold standard** for screening and can assess risk levels and severity. *Why not SADQ alone?* - **SADQ** (Severity of Alcohol Dependence Questionnaire) is primarily a **severity assessment tool**, not a screening tool. - It is a 20-item instrument used to measure the **degree of alcohol dependence** in individuals already identified with alcohol problems. - While valuable for treatment planning, SADQ is more detailed and designed for assessment rather than initial screening [1]. - However, all three tools are validated and used in alcohol use disorder evaluation - CAGE and AUDIT for screening, SADQ for severity assessment.
Question 2: What is considered the most effective treatment for Borderline Personality Disorder?
- A. Combination of DBT and pharmacotherapy
- B. Cognitive Behavioural Therapy (CBT)
- C. Pharmacotherapy alone
- D. Dialectical Behaviour Therapy (DBT) (Correct Answer)
Explanation: ***Dialectical Behaviour Therapy (DBT)*** - **DBT** is the **gold standard** and most evidence-based psychotherapy specifically developed for Borderline Personality Disorder - Developed by **Marsha Linehan** specifically to target the core symptoms of BPD including emotional dysregulation, impulsivity, and interpersonal difficulties - Combines **cognitive-behavioral techniques** with mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness skills - Has the **strongest research evidence** for reducing suicidal behavior, self-harm, and improving overall functioning in BPD patients - Multiple RCTs demonstrate DBT's superiority in treating BPD compared to standard care *Cognitive Behavioural Therapy (CBT)* - While **CBT** is effective for many mental health conditions and can help with certain BPD symptoms, it was not specifically designed for BPD - DBT is actually a specialized adaptation of CBT tailored for BPD, making it more targeted and effective for this specific condition - Generic CBT may help with co-occurring conditions like depression or anxiety but lacks the comprehensive approach needed for core BPD features *Combination of DBT and pharmacotherapy* - This combination is clinically useful, especially when treating **co-morbid conditions** like depression, anxiety, or severe mood instability - However, psychotherapy (particularly DBT) remains the **cornerstone** of BPD treatment, with medications serving an adjunctive role - The question asks for the single most effective treatment, which is DBT alone *Pharmacotherapy alone* - **No medication** is FDA-approved specifically for BPD - Pharmacotherapy may help manage specific symptoms (mood swings, impulsivity, brief psychotic episodes) but does not address the core **personality pathology** - Generally not recommended as monotherapy for BPD; should always be combined with psychotherapy
Question 3: Atomoxetine is used in the management of which of the following conditions?
- A. Bipolar disorder
- B. Schizophrenia
- C. Depression
- D. ADHD (Correct Answer)
Explanation: ***Correct: ADHD*** * **Atomoxetine** is a **selective norepinephrine reuptake inhibitor (SNRI)** primarily used in the management of **Attention-Deficit/Hyperactivity Disorder (ADHD)**. * It is a **non-stimulant** medication, making it a suitable alternative for patients who do not respond to or cannot tolerate traditional stimulant medications for ADHD. * FDA-approved in 2002, atomoxetine remains an important treatment option, particularly for patients with concerns about stimulant abuse potential or those with comorbid anxiety disorders. *Incorrect: Bipolar disorder* * **Bipolar disorder** is typically treated with mood stabilizers (e.g., lithium, valproate), antipsychotics, and sometimes antidepressants, but atomoxetine is not a first-line or common treatment option. * While some ADHD symptoms can overlap with bipolar disorder, atomoxetine is specifically designed for ADHD and lacks the broad mood-stabilizing effects needed for bipolar disorder. *Incorrect: Schizophrenia* * **Schizophrenia** is a severe mental disorder treated primarily with **antipsychotic medications** that target dopamine and serotonin systems. * Atomoxetine does not have efficacy in treating the positive or negative symptoms of schizophrenia and is not indicated for this condition. *Incorrect: Depression* * While atomoxetine affects **norepinephrine**, some SNRIs (e.g., venlafaxine, duloxetine) are used for depression. However, atomoxetine's primary indication and efficacy profile are not for treating **major depressive disorder**. * Its mechanism of action is more specifically tailored to the neurochemical imbalances seen in ADHD rather than the broader neurotransmitter dysregulation in depression.
Question 4: In which of the following conditions is behavior therapy considered most effective?
- A. Panic Attack
- B. Psychosis
- C. Obsessive-Compulsive Disorder (OCD) (Correct Answer)
- D. Generalized Anxiety Disorder
Explanation: ***Obsessive-Compulsive Disorder (OCD)*** - **Exposure and Response Prevention (ERP)**, a type of behavior therapy, is the gold standard and most effective treatment for OCD. - ERP directly targets the **obsessions** and **compulsions** by gradually exposing individuals to feared situations without allowing them to perform their rituals. - OCD shows the **highest response rates** to pure behavior therapy compared to other psychiatric conditions. *Psychosis* - While supportive therapy and cognitive behavioral therapy for psychosis (CBTp) can be helpful, **behavior therapy alone is not considered the primary or most effective treatment** for core psychotic symptoms. - Management of psychosis primarily relies on **antipsychotic medications** to address symptoms like hallucinations and delusions. *Panic Attack* - Behavior therapy and CBT are effective for **Panic Disorder**, but the effectiveness is somewhat lower than for OCD. - Treatment for panic disorder often requires a **combination of behavioral and cognitive techniques** rather than pure behavior therapy alone. - Management typically includes breathing exercises, exposure to physical sensations, and cognitive restructuring. *Generalized Anxiety Disorder* - **Cognitive Behavioral Therapy (CBT)**, which includes behavioral components, is highly effective for GAD, but the **cognitive elements are essential** for addressing worry and rumination. - Pure behavior therapy (e.g., systematic desensitization) is less effective for GAD compared to OCD, as GAD involves pervasive cognitive distortions that require cognitive restructuring.
Question 5: Which of the following treatments cannot be used for management of Obsessive Compulsive Disorder (OCD)?
- A. Fluoxetine
- B. Carbamazepine (Correct Answer)
- C. Cognitive Behaviour Therapy
- D. Clomipramine
Explanation: ***Carbamazepine*** - **Carbamazepine** is an **anticonvulsant** and **mood stabilizer** primarily used for epilepsy and bipolar disorder. - It does not have established efficacy for the treatment of **Obsessive-Compulsive Disorder (OCD)**. *Fluoxetine* - **Fluoxetine** is a **Selective Serotonin Reuptake Inhibitor (SSRI)** and is a **first-line pharmacotherapy** for OCD. - SSRIs, including fluoxetine, are effective in reducing the severity of **obsessions and compulsions**. *Cognitive Behaviour Therapy* - **Cognitive Behavioural Therapy (CBT)**, specifically **Exposure and Response Prevention (ERP)**, is the **gold standard psychotherapy** for OCD. - It involves gradually exposing patients to feared situations or thoughts while preventing their ritualistic responses. *Clomipramine* - **Clomipramine** is a **tricyclic antidepressant (TCA)** that has potent inhibitory effects on **serotonin reuptake**. - It is one of the **most effective medications** for OCD, often used when SSRIs are insufficient.
Question 6: A patient stopped alcohol consumption for 3 days and presented with irritability, disorientation, paranoid delusions, agitation, visual hallucinations, and altered sensorium. What is the likely diagnosis in this case?
- A. Wernicke's encephalopathy
- B. Alcohol withdrawal delirium (Correct Answer)
- C. Korsakoff's psychosis
- D. Alcohol intoxication
Explanation: ***Alcohol withdrawal delirium*** - The combination of **irritability, disorientation, paranoid delusions, agitation, visual hallucinations, and altered sensorium** developing 3 days after cessation of alcohol is classic for **delirium tremens**, the most severe form of alcohol withdrawal. - This condition is a medical emergency that can lead to seizures, cardiovascular collapse, and death if not treated promptly. *Wernicke's encephalopathy* - Characterized by the triad of **ataxia, ophthalmoplegia, and confusion**, which is due to **thiamine deficiency** and is not fully consistent with the patient's presentation. - While it can occur in chronic alcoholics, the rapid onset of severe agitation, hallucinations, and paranoia points more towards active withdrawal. *Korsakoff's psychosis* - This is a chronic neuropsychiatric syndrome that typically follows untreated Wernicke's encephalopathy, characterized by severe **anterograde and retrograde amnesia** and **confabulation**. - It does not present with the acute delirium, agitation, and prominent hallucinations described. *Alcohol intoxication* - This occurs when a person has recently consumed a large amount of alcohol, leading to symptoms like **slurred speech, impaired coordination, mood changes, and reduced inhibition**. - The patient's symptoms are occurring *after* stopping alcohol consumption for 3 days, indicating withdrawal, not active intoxication.
Question 7: Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Explanation: ***A-4, B-1, C-3, D-2*** - **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms. - **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes. - **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development. - **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation. *A-1, B-3, C-2, D-4* - This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications. - It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy. *A-3, B-2, C-4, D-1* - This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications. - It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation. *A-2, B-4, C-1, D-3* - This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications. - It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Question 8: Which of the following statements accurately describes dual sex therapy?
- A. It may include the use of medications like sildenafil.
- B. It focuses on improving intimacy and communication between partners.
- C. It is designed for couples experiencing sexual dysfunction.
- D. Dual sex therapy involves treatment of both partners. (Correct Answer)
Explanation: ***Dual sex therapy involves treatment of both partners.*** - **Dual sex therapy** is a therapeutic approach where both partners in a relationship participate in the treatment process. - This is because sexual dysfunction often has **interpersonal dynamics** and addressing both individuals' perspectives and behaviors is crucial for effective intervention. - The "dual" aspect specifically refers to the joint participation of **both partners** in therapy, which is the defining characteristic of this approach. *It focuses on improving intimacy and communication between partners.* - While improving **intimacy and communication** is often a goal and an outcome of successful sex therapy, it is not the defining characteristic of "dual sex therapy" specifically. - The core of **dual sex therapy** is the joint participation of both partners in the treatment, not just the therapeutic goals. *It is designed for couples experiencing sexual dysfunction.* - **Dual sex therapy** is indeed designed for couples experiencing sexual dysfunction, but this statement describes the *purpose* rather than the *nature* of the therapy itself. - The "dual" aspect specifically refers to the involvement of **both partners** in the therapeutic process, not just the target population. *It may include the use of medications like sildenafil.* - The use of **medications** like sildenafil (Viagra) is a common adjunct treatment for erectile dysfunction and other sexual dysfunctions, but it is a **pharmacological intervention**, not a characteristic of "dual sex therapy" per se. - **Dual sex therapy** primarily refers to the psychotherapeutic approach involving both partners rather than specific medical treatments.
Question 9: Provision of the Mental Health Act 2017, based on WHO guidelines, includes all, except:
- A. Social support
- B. Screening family members (Correct Answer)
- C. Human rights
- D. Communication regarding care and treatment
Explanation: ***Screening family members*** - The Mental Health Act 2017 focuses on the **rights, treatment, and support of individuals with mental illness**, not routine screening of their family members. - The Act does not contain provisions mandating **screening of asymptomatic family members**, though family history may be relevant for clinical assessment. - This is **not a provision** outlined in the Act based on WHO guidelines. *Human rights* - The Act is explicitly grounded in the **protection and promotion of human rights** for persons with mental illness (Chapter I). - Ensures care with **dignity, respect, and freedom from discrimination** as core principles. - Aligns with WHO's mental health action plan and human rights framework. *Communication regarding care and treatment* - **Section 4** emphasizes the right to information and **informed consent** for all treatment decisions. - Patients must receive clear communication about their **diagnosis, treatment options, and care plans**. - Includes provisions for **advance directives** and involvement in treatment decisions. *Social support* - **Chapter V** addresses rehabilitation and community-based services, emphasizing the role of **social support systems**. - Promotes **community integration** and access to social resources for recovery. - Recognizes family and community support as essential for long-term mental health management.
Question 10: Choose the correctly matched pairs regarding the drugs used in schizophrenia: 1. D2 antagonism: Reduces positive symptoms 2. 5HT2A antagonism: Reduces negative symptoms 3. 5HT1A agonism: Weight loss 4. Muscarinic antagonism: Reduces extrapyramidal symptoms
- A. 1,4
- B. 1,2,4
- C. 1,2,3,4
- D. 1,2 (Correct Answer)
Explanation: ***1,2*** - **D2 antagonism** is the primary mechanism by which antipsychotics reduce **positive symptoms** of schizophrenia, such as hallucinations and delusions. - **5HT2A antagonism** is a key mechanism of atypical antipsychotics contributing to the reduction of **negative symptoms** (e.g., apathy, anhedonia, flat affect) and cognitive deficits, while also reducing the risk of extrapyramidal symptoms. *1,2,3,4* - This option is incorrect because **5HT1A agonism** is not associated with **weight loss**. While 5HT1A partial agonism (as seen with aripiprazole and brexpiprazole) may improve negative symptoms, anxiety, and cognitive function, it does not directly cause weight loss. - Additionally, **muscarinic antagonism** does not reduce extrapyramidal symptoms as a primary mechanism. Rather, anticholinergic (muscarinic antagonist) drugs like benztropine are used to **treat** EPS after it occurs. The reduction of EPS in atypical antipsychotics primarily comes from 5HT2A antagonism and lower D2 binding affinity. *1,2,4* - This option is incorrect because **muscarinic antagonism** is not a mechanism that reduces EPS. Anticholinergic agents are used therapeutically to counteract EPS caused by dopamine blockade, but anticholinergic effects themselves do not prevent or reduce EPS. - The reduction of EPS with atypical antipsychotics is mainly due to **5HT2A antagonism** balancing dopaminergic blockade, selective limbic over striatal binding, and fast D2 dissociation kinetics. *1,4* - This option is incorrect because it omits **5HT2A antagonism**, which is crucial for reducing **negative symptoms** in schizophrenia. - It also incorrectly includes muscarinic antagonism as a mechanism that reduces EPS, when in reality anticholinergics are used to treat EPS rather than prevent it.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free